HCV In TheNews
Incivek/Telaprevir
Victrelis/Boceprevir
Telaprevir with VX-222
Archives 2011-2010
Telaprevir
Boceprevir
Hepatitis C Treatment:
New targets for antiviral therapy
Side effects-direct-acting antivirals
Drug Interaction Charts
Telaprevir/Boceprevir/Peg-IFN alfa
2012
UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients
2011
An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases
Check Out The New Website
Hepatitis C New Drug Research And Liver Health
RSS Feed;
Updates On The New Website
Updated Feb-2012
If you have just been diagnosed with hepatitis C or considering HCV therapy click here for easy to understand information.
Both of the new medicines work by blocking a protein called protease that the virus needs to replicate
How Do I Take Incivek-telaprevir ?
Included in the information will be the dosing regimen for Incivek in combination with pegIFN/RBV, and a list of drugs that could cause drug interactions if used while taking the combo.
Hepatitis C-New Protease Inhibitor (NS3/4A) Drug Resistance Test
LabCorp has begun offering nationwide its hepatitis C GenoSure NS3/4A assay, which is designed to identify NS3 and NS4A mutations and NS3-associated resistance to a pair of recently approved HCV protease inhibitors.
HCV Genotypes and new possible therapies
Investigational drugs in the treatment of genotype 4
Hepatitis C virus resistance to protease inhibitors
Patient video; New hepatitis C Drugs and Resistance
Hepatitis C: current management and emerging therapies
New Drug Pipeline
New drugs in development for the treatment of hepatitis C
Telaprevir FDA Approved
Oct 11
INCIVEK(TM) (telaprevir) Now Available in Canada
Sept 20
European approval for hepatitis C drug, Telaprevir-Incivek "called Incivo in Europe."
Health Canada Okays INCIVEK For People With Hepatitis C
FDA Approves Telaprevir/Incivek For Hepatitis C
Boceprevir FDA Approved
Nov 22
Ontario first province to reimburse new chronic hepatitis C treatment VICTRELIS™ Now Available for Eligible Patients in Ontario
The Canadian Liver Foundation is pleased that Ontario’s public drug program has agreed to reimburse boceprevir for the treatment of chronic hepatitis C,” says Dr. Morris Sherman, Chairman of the Canadian Liver Foundation. “Boceprevir represents a major advance in our ability to cure this disease, and as a result, fewer patients will have to struggle with the consequences of end-stage liver disease, liver transplants and liver cancer. We applaud the research efforts that led to this breakthrough and hope other provinces will follow Ontario’s lead and rapidly reimburse this important treatment.”
Health Canada Clears Victrelis-Boceprevir New Hepatitis C Drug
MSD launches hepatitis C drug Victrelis in UK
Vicrelis/Boceprevir IS NOW FDA Approved May 13 2011
Patient Assistance Program
INCIVEK/Telaprevir and VICTRELIS (Boceprevir) Patient Assistance Programs
Of Interest
Use of New HCV Protease Inhibitors ‘Not That Simple’
Incivek/Victrelis; New approvals may change treatment for hepatitis C
FYI-Which New Hepatitis C Drug do MDs Prefer? Incivek vs. Victrelis
New Treatments For Hepatitis C; Boceprevir vs Telaprevir: What We Know and Don't Know
Getting Ready; Telaprevir or Boceprevir?
Boceprevir-victrelis-Which pegylated interferon?
Worth Reading
FDA Transcripts Telaprevir/Boceprevir April Advisory Committee Meeting Includes Side Effects
Medication Guides;
Telaprevir/Incivek Prescribing Information
Medication Guide
VICTRELIS™- Boceprevir: Prescribing Information and Medication Guide
Peginterferon alfa
Ribavirin
Free from Hepatitis C:Your Complete Guide to Healing Hepatitis C (Dec 1, 2011 release); Click on the book to learn more.
- A Guide 2011-Management Of HCV (1)
- A-Current status and future directions in the management of chronic hepatitis C (1)
- A-New targets for antiviral therapy (8)
- AASLD 2011 updated hepatitis C practice guidelines (2)
- AASLD 2012-STC (1)
- AASLD Nov 2011 (60)
- AASLD Nov 2011-Pocasts-Videos-Webcasts (1)
- AASLD Nov 2011-Summary (1)
- AASLD Oct2010 (80)
- AASLD Oct2010-summary (1)
- ABT-450 (4)
- Acai Berry Scam (1)
- ACH-1625 (11)
- ACH-2684 (2)
- ACH-2928 (2)
- ACH-3102 (1)
- ACLF (1)
- acute HCV (3)
- acute liver failure (1)
- addiction (8)
- Adherence to therapy (7)
- ADI-PEG 20 (1)
- AIDS (2)
- alisporivir (1)
- ALS-2200 and ALS-2158 (2)
- ANA598 (5)
- ANA598-setrobuvir (1)
- ANA773 (1)
- ANA958 (1)
- anemia (3)
- antidepressants (3)
- arthritis (2)
- ascites (3)
- asthma (1)
- autoimmune hepatitis (1)
- Avila Therapeutics™ (1)
- AVL-192 (2)
- bath salts-spice (7)
- Bavituximab (5)
- BCX5191 (1)
- Behind the Headlines (1)
- Behind the Headlines-Vaccine (1)
- Best Hospitals (4)
- BI 201335 (13)
- BI 201335 and BI 207127 (3)
- BI 207127 (6)
- BILB 1941 (1)
- Bioartificial Liver (3)
- biological "devices" to program cells (1)
- BioScience (2)
- biosimilars (4)
- BIT225 (1)
- blood safety (1)
- blood scandal (3)
- bms-650032 (5)
- BMS-650032 (Asunaprevir) BMS-790052 (Daclatasvir) (2)
- BMS-650032 and BMS-790052 (4)
- bms-790052 (17)
- bms-790052-declatasvir (1)
- boceprevir (96)
- Boceprevir FDA Transcript (1)
- boceprevir patient guide (1)
- boceprevir-drug assistance program (3)
- boceprevir-Medication Guide-Prescribing Info (1)
- boceprevir-victrelis (75)
- boceprevir-victrelis-Cost (1)
- boceprevir-victrelis-mericitabine w-SOC (1)
- Bowel (1)
- Brain (2)
- Caleco Pharma (1)
- Canada (1)
- cancer (6)
- cancerous growths gallbladder and/or the bile duct (1)
- CDC (2)
- CDC- World Hepatitis Day 2011 (1)
- Chat room (3)
- children treating HCV (9)
- chronic disease (2)
- chronic fatigue (14)
- chronic hepatitis c (1)
- chronic liver failure (2)
- chronic pain (3)
- cirrhosis (109)
- clinical trials (67)
- clinical trials-Pro-Con (2)
- coffee (10)
- Colloidal silver (1)
- compensated cirrhosis (9)
- Complementary and Alternative Medicine (9)
- Counterfeit drugs (5)
- covalent inhibitor (2)
- Creating Functional Hepatic Tissue (1)
- Cryoglobulinemia (4)
- CTS-1027 (5)
- Daclatasvir/Asunaprevir (1)
- Daily Consensus Interferon (1)
- Danoprevir (7)
- DDW 2011 Meeting (11)
- DEB025 (2)
- DEB025- alisporivir (3)
- decompensated cirrhosis (15)
- Dental (2)
- Depression (8)
- diabetes (76)
- diabetes-insulin resistance (4)
- Digestion (1)
- Direct-acting Antivirals (8)
- disease progression (8)
- donation (5)
- drug alerts (1)
- Drug Assistance Programs (4)
- dry eye (1)
- EASL (60)
- EASL-Summary (1)
- ELAD® Bioartificial Liver (1)
- encephalopathy (16)
- endoscopy (1)
- Epidemic HCV (9)
- Epogen (3)
- ESLD (1)
- fatigue (5)
- Fatty Liver (67)
- FDA (54)
- fibromyalgia (4)
- Fluvastatin (1)
- Foodborne illness (11)
- G7128 (1)
- gallbladder (1)
- gallstones (7)
- Gastroenterologist (1)
- geno 2 (2)
- geno1 (56)
- geno2 (23)
- geno3 (32)
- geno4 (17)
- geno5 (4)
- geno6 (7)
- genotypes;All (10)
- green tea (2)
- GS-7977 Formally/PSI-7977 (5)
- GS-9190 (6)
- GS-9256 (5)
- Gut Bacteria (1)
- HALL OF SHAME (32)
- HALT-C (5)
- hav (5)
- hbv (64)
- HCV Australia (1)
- hcv abstracts (169)
- HCV Awareness (23)
- HCV Forum (1)
- HCV News (403)
- HCV pregnancy (5)
- HCV replication (3)
- HCV research (30)
- HCV Self-management (1)
- HCV symptoms (2)
- HCV tests (17)
- HCV tests-endoscope (1)
- HCV Vaccine (16)
- HCV vaccine GI-5005 (6)
- HCV Vaccine-TG4040 (MVA-HCV) (1)
- HCV Worldwide (21)
- HCV Worldwide Asia Australia Egypt (1)
- HCV Worldwide-Europe Canada Israel (1)
- HCV Your Health (3)
- HCV-Breast Cancer Risk (1)
- HCV-Editorial (2)
- HCV-Insulin resistance (2)
- HCV-Statins (2)
- HCV/HBV/HIV special populations (1)
- Health Reform (2)
- Health Reform-Insurance (2)
- Healthy you (14)
- hemochromatosis (1)
- Hepatitis-related Renal Disease (1)
- hepatologist (1)
- hepatoSys Virtual Liver Network (1)
- herb (26)
- herb-kava (1)
- HEV (2)
- History of HCV (3)
- HIV (81)
- HIV-children (1)
- HIV/HCV (38)
- hot topic (8)
- HTAs-host-targeting agents (1)
- human genome (5)
- human interferon alpha lozenges (1)
- Idenix Reports Positive Interim Data for Hepatitis C Drug (1)
- IDX184 (4)
- IDX184/on hold (2)
- IDX184/on hold-removed (1)
- IDX320/pulled (2)
- if I had.. (9)
- IL-7(CYT 107) (1)
- IL28B (39)
- IL28B Test (1)
- immune system (8)
- IMO-2125 (6)
- Inflammation (1)
- Inflammation Liver (1)
- Inflammatory Bowel Disease (1)
- Inspirational (23)
- Insurance (1)
- Insurance medicare (1)
- interferon (1)
- Interferon Free Combinations (37)
- Interferon lambdas (1)
- Investment News HCV Drugs (22)
- INX 189 (12)
- IP-10 (1)
- ITX-5061 (1)
- Joint pain (1)
- Just for fun (2)
- JX594/TG6006 (1)
- Lambda (1)
- Lichen Planus (3)
- List Peer-Reviewed Journals (1)
- Liver Abscess (2)
- liver biopsy (9)
- liver biopsy-necessary in all genotypes? (1)
- liver cancer (130)
- Liver cancer CF102 (2)
- Liver Cancer Treatment (61)
- liver cancer treatment-radiofrequency ablation (RFA) (1)
- Liver Cancer-HEAT Study of ThermoDox(R) (1)
- liver cancer-MCT-465 and MCT-485 (1)
- liver cancer/sorafenib (1)
- Liver Cysts (1)
- liver disease (5)
- Liver Fibrosis (53)
- liver function tests (10)
- liver health (55)
- Liver Injury Dietary Supplements (1)
- Liver Pain (6)
- liver surgery (2)
- locteron (1)
- Locteron/interferon (2)
- lymphoma (2)
- M11-602 (1)
- marijuana (20)
- marijuana-based prescription drug (1)
- Men and HCV (2)
- microspheres (3)
- Milk thistle (15)
- Miravirsen (2)
- MK-5172 (1)
- MK-7009 (1)
- Morbidity-SVR (1)
- Mortality (6)
- myocarditis (1)
- nanoparticles (2)
- Nanotechnology (1)
- Natural leukocyte interferon alpha (Alfaferone) (1)
- Neutropenia HCV Treatment (3)
- new drugs (2)
- new hcv drugs (55)
- newly diagnosed (6)
- newsletters (30)
- Nitazoxanide (1)
- noninvasive tests for fibrosis (24)
- nonresponders (6)
- NSAID (5)
- null responders (8)
- Off Topic (25)
- organ harvesting (7)
- organ trafficking (3)
- organ trafficking- U.S (1)
- Other Conditions Related To HCV (38)
- Other Conditions Related To HCV-Vasculitis (4)
- Other Health News (66)
- OTHER INFECTIOUS DISEASE (19)
- outsourcing clinical trials (3)
- outsourcing drugs (7)
- partial responders (3)
- Pediatric liver disease (1)
- Pegasys (8)
- Peginterferon (54)
- PegIntron (4)
- Peripheral Neuropathy (1)
- PF-05095808 (1)
- Pharmaceuticals (55)
- platelets (1)
- polymerase inhibitor (11)
- Porphyria Cutanea Tarda (PCT) (1)
- Post Treatment Symptoms (1)
- PPI-461 (3)
- PPI-668 (2)
- primary biliary cirrhosis (PBS) (1)
- probiotics (1)
- procrit (4)
- prognostic test:response to therapy (1)
- prostate cancer (1)
- protease inhibitor (23)
- protease inhibitor- (NS3/4A) Drug Resistance Test (2)
- PSI-7977 (25)
- PSI-7977 and PSI-938 (1)
- PSI-7977-TMC435 (2)
- PSI-7977/ Daclatasvir-(BMS-790052) (1)
- PSI-938 (6)
- PSI-938-Halted (1)
- Pulmonary fibrosis (1)
- Quackery (9)
- Questions About HCV (4)
- rash (6)
- recall (20)
- regeneration (5)
- regenerative Medicine (11)
- relapse (3)
- resistance to protease inhibitors (13)
- response-guided therapy (1)
- RG7128 (9)
- ribavirin (15)
- Ritonavir (1)
- rituximab (2)
- salt (4)
- scientists grow human livers in laboratory (7)
- SCY-641 (1)
- Seasonal Flu Vaccine (3)
- selenium (1)
- setrobuvir (1)
- side effects (49)
- side effects-direct-acting antivirals (5)
- side effects-eyes (4)
- side effects-telaprevir (1)
- silymarin (1)
- SIR-Spheres microspheres (2)
- Small fiber neuropathy (2)
- Sorafenib (2)
- SPC3649-(Miravirsen) (1)
- sphincter of Oddi (3)
- spleen (5)
- SPONTANEOUS CLEARANCE (8)
- Starting HCV Treatment (47)
- STAT-C (3)
- stem cell tourism (5)
- stem cell-diabetes (1)
- stem cells (50)
- stem cells-pluripotent (2)
- supplements (6)
- support (21)
- support-hotline (1)
- Surgery in liver disease (1)
- svr (47)
- SVR-Mortality (1)
- svr-pitavastatin (Livalo) (1)
- svr-rapid response (1)
- Tattoos (1)
- telaprevir (121)
- Telaprevir FDA Transcript (1)
- telaprevir medication guide (1)
- telaprevir patient assistance (3)
- telaprevir prescribing information (1)
- telaprevir with VX-222 (17)
- telaprevir-incivek (92)
- telaprevir-incivek-Cost (2)
- Tenofovir (2)
- Terry's nails (1)
- TG4040 (1)
- Thalidomide (1)
- Therapy-over the age of 65 (1)
- TheraSphere (1)
- Thrombocytopenia (3)
- thrombosis (2)
- thyroid (7)
- Timeline Hepatiits (1)
- TMC278 for HIV (1)
- TMC435 (22)
- TMC435-BMS-790052 (1)
- TMC649128 (4)
- toxicity (21)
- transmission (44)
- Transmission clinical setting (36)
- Transmission of HCV Through Transplanted Organs (1)
- transmission-needlestick (1)
- transplant (110)
- transplant tourism (7)
- transplant-HCV recurrence (1)
- transplant-IL28B (1)
- transplant-MELD (4)
- Triad Prep Pads (14)
- tylenol (2)
- upper abdominal pain (1)
- varices (12)
- video (208)
- video viral load test(PCR) (1)
- viral load (6)
- Virtual Liver (1)
- virus research (2)
- vitamin A (1)
- vitamin B12 (1)
- vitamin D (25)
- vitamin E (4)
- Vitamin E-TE/TCP supplements (1)
- vitamin k (1)
- vitamins (5)
- wellness (52)
- what is hepatitis c (1)
- women (5)
- Xifaxan (1)
- zalbin (1)
Part One: Hey Can I Get Hepatitis C From......
Part Two: Hey, I Have A Question About HCV Tests
Part Three : Hey,I Have Questions About Cirrhosis And My Liver......
Part Four: Thirty Eight Questions About Hepatitis C
Part Five: Hey, I have a question about this IL28B gene and hepatitis c treatment.....
Part Six: Do I still need a liver biopsy? What Is A Noninvasive Test For Fibrosis ?
Treatment Side Effects
Skin Rash During Chronic Hepatitis C Therapy
HCV Treatment and Neutropenia(low white count)
Older HCV Patients Have More Side Effects
Chronic cough/Pegylated interferon/ribavirin In HCV Therapy
Interferon-α induced severe thrombocytopenia: A case report and review of the literature
Other HCV Sites:
These links will take you to the premier Hepatitis C sites and keep you informed with breaking news, clinical studies, new drugs, podcasts, newsletters, support, personal experiences, chat rooms, forums and more.
AASLD
The American Association for the Study of Liver Diseases November 2011 Annual Meeting
AASLD-Liver Learning
If you haven't yet explored the "Liver Learning" section available @ the AASLD web site you're missing out on the November meeting webcasts, video podcasts, abstracts and more.
Web Site
AASLD Coverage Available On The Web Site
This AASLD Summary attempts to present recent data in an accessible format providing a greater understanding of current and future gentler HCV therapies that could be available in the near future.
Included are many of the investigational second-generation protease inhibitors and Interferon-free treatment regimens presented at this months meeting.
-
▼
2012
(192)
-
►
March 2012
(15)
- INCIVEK interim results:74% People Co-Infected wit...
- Clinical Implications of HCV Resistance: Laying th...
- First guidelines issued for getting people newly d...
- Idenix Pharmaceuticals Announces Declaration of a ...
- Researchers Pursue Promising New Approach in the T...
- Scientists have shed light on how the liver repair...
- News Ticker - Hepatitis-C Concerns Grow
- News Ticker-Nails,Skin,Coffee,Fibrosis,HCV Inflamm...
- Hepatitis C-Current status and future directions i...
- HCV therapeutics: Times are changing
- View List-FDA Alert-Statins and HIV or Hepatitis C...
- Inflammation and depression unraveled
- Hepatitis C Virus Persistence After Sustained Viro...
- Gilead Hepatitis C Setback Opens Door to Rivals
- How Interferon Works to Suppress Virus in Patients...
-
►
February 2012
(64)
- New Antivirals Show Promise for an Interferon-free...
- Ultrasound technology proves accurate in diagnosin...
- Hepatitis C News - New Drug Research
- Interferon-free combination GS-7977/Ribavirin Will...
- Stanford scientists model hepatitis C treatment op...
- News Ticker:Serum Vitamin D Levels Are Not Predict...
- UK consensus guidelines for the use of the proteas...
- Weekend News Ticker:Video/Treating hepatitis C
- HCV News Ticker - Friday Round-Up
- Vertex Study:Interferon-Free (All-Oral) Regimen of...
- News Ticker: Watch Hepatitis C and Baby Boomers
- News Ticker-Patients’ Expectations About New HCV D...
- Hepatitis C Now Kills More Americans Than HIV
- Baby boomers most at-risk for hepatitis C as death...
- A significant step forward in Hep-C prevention
- Weekend Reading: Paper Device Monitors Liver Healt...
- Bristol-Myers Squibb Foundation Announces Grants F...
- GS-7977: Hard-to-Treat Group Trips Up Hepatitis C ...
- ACH-1625 Discussed in Oral Presentation at 2012 As...
- GS-7977-formally PSI-7977 Viral Relapse Seen Post ...
- J&J Consumer Health Unit Recalls Infant Tylenol
- News Ticker: Fake Drugs - All At a Pharmacy Near Y...
- The Era of Direct-acting Antivirals Has Begun-The ...
- Tune In to Hep C
- U of A researchers move closer to discovering hepa...
- Drugmakers Jockey for Piece of Future Hepatitis C ...
- Hepatitis C-Preclinical Results For BCX5191
- Hepatitis C News Ticker
- IDX-184-Idenix CEO on Hep C Drug Study - CNBC
- Vitamin E Tocotrienol Supplement Delays Progressio...
- In Small Pilot Study, Some Pediatric Liver Recipie...
- Antiviral activity of TMC435 monotherapy in patien...
- HCV News Ticker: Big Pharma Monday Madness
- Gilead, Vertex and the Mystery of Missing Hep C Pa...
- Bristol-Myers Squibb Announces Successful Completi...
-
▼
January 2012
(113)
- Video-New and experimental oral drugs to treat hep...
- Hepatitis C Drug Victrelis-Boceprevir released for...
- Stem cells may shed light on hepatitis C, MIT rese...
- Hepatitis C News Ticker: The ELF test-Blood Test I...
- The Effect of Caffeine and Alcohol Consumption on ...
- Fatigue in Cirrhosis: Is Transplant the Answer?
- The phenotypic fate and functional role for bone m...
- Hepatitis C-Clinical evidence for the regression o...
- Why Boomers Should Be Aware of Hepatitis
- Once-weekly diabetes drug wins approval on third t...
- Muscle and Mortality in Cirrhosis
- The 2012 AASLD Hepatitis Single Topic Conference (...
- Friday Round Up - Hepatitis News Ticker:
- Entry point of hepatitis C virus identified
- Germany’s IQWiG sees added benefits for Incivo
- Big Pharma:The Hepatitis C Race For Tolerable Ther...
- Pharmasset's Hepatitis C Drug: How it Could Change...
- Watch-Beware of Hepatitis B at the nail salon
- Magic mushrooms point to new depression drugs
- Pot-based prescription drug looks for FDA OK
- Drop in effectiveness of HCV treatment in national...
- New Hepatitis C Regimen Stimulates Changes in Ther...
- Your liver is for life - so treat it well
- Hepatitis C Virus Infection In Non-Hodgkin’s Lymph...
- Off Topic- 6 Devices That Could Change the Standar...
- Dietary Fiber for the Treatment of Type 2 Diabetes...
- Editorial-How to Optimize Treatment of Hepatitis C...
- Surveillance for Hepatocellular Carcinoma in Patie...
- Diabetes-Biochip measures glucose in saliva, not b...
- Gender Differences in Liver Cancer Risk Explained ...
- Hepatitis C Friday News Ticker: How far is noninva...
- Hepatitis C-From Clinical Guidelines to Clinical P...
- New developments in HCV therapy
- How far is noninvasive assessment of liver fibrosi...
- Steatosis and insulin resistance in response to tr...
- Yes! Statins can be given to liver patients
- Risk factors for hepatocellular carcinoma in diabe...
- Achillion's Hep C Pipeline Likely Can't Compete
- Daclatasvir and Asunaprevir:New Drug Combo for Hep...
- U.S. Food and Drug Administration Approves New For...
- Boceprevir and telaprevir for hepatitis C: safety ...
- Factors linked to severe thrombocytopenia during a...
- Virology Blog - Review cell proteins essential for...
- Scientists show brain vulnerable to Hepatitis C vi...
- Rituximab Helpful Against HCV Cryoglobulinemic Vas...
- Scientists develop new gallbladder endoscopy
- Video-FDA Grants Fast-Track Status to Achillion’s ...
- Dermatological side effects of hepatitis C and its...
- ArQule advances drug candidate - (Tivantinib) for ...
- Behind the Headlines - Blood vessels 'grown in lab...
- Hepatitis C- Accurate, clinically relevant informa...
- UBC researchers identify potential new therapy app...
- Mass. General researchers find novel way to preven...
- Developments in hepatitis C treatment
- Direct acting antivirals for the treatment of chro...
- THE END OF THE BEGINNING FOR HEPATITIS C TREATMENT...
- Arizona clinic linked to illegal stem cell treatme...
- A Viral Dynamic Model for Treatment Regimens with ...
- AASLD- Response to Comments on An Update on Treatm...
- Idenix Seeks Partner for Hepatitis C Combination D...
- Morning HCV News Ticker:Walgreen Overcharging For ...
- LSUHSC research identifies 'bath salts' as new sou...
- FDA Holds OJ Imports Pending Fungicide Testing
- Slowly digested carbs reduces markers of inflammat...
- Viral load a major factor affecting risk of sexual...
- Hype-atitis C? Analysts worry about a bubble formi...
- Minimal Transmission of HIV Despite Persistently H...
- Hepatitis C drug set to give Cardiff University fi...
- Chronic liver disease and cirrhosis makes the list...
- Vitamin D supplementation improves sustained virol...
- Dr. Douglas Dieterich: Hepatitis C Video
- Hepatitis C - Five Ways You Can Take Care of Your ...
- All About; Incivek (Telaprevir)-An Oral Protease I...
- Stem Cell Therapy May Reverse Diabetes
- Behind the Headlines-Experimental hepatitis C vacc...
- Hepatitis C Newsletters-Jan 2012
- High Rates of Disability and Health Care Use Found...
- New fibrosis classification improves accuracy of d...
- Phase IIb NASH/Fatty Liver trial cleared without F...
- Merck's Goal Is To Be A Leader In Hepatitis C Trea...
- Examining the dangers of stem cell tourism
- Trash the Vitamins: Convince Your Patients
- World-Renowned Hepatologist Emmet B. Keeffe, M.D.,...
- Radiofrequency ablation appears to have similar ef...
- Predictors Identified for Posttransplant Recurrenc...
- Hepatitis C-Presidio Phase 1a dose-ranging assessm...
- Idenix-Phase 2B trial of IDX184 Reports Positive I...
- Benitec Biopharma hepatitis C therapeutic pre-clin...
- Hepatitis C - Sunday Reading Round Up
- Bristol-Myers Squibb to Acquire Inhibitex
- India's Drug Trials-Thousands have died since rule...
- Stem Cell Preconditioning Boosts Liver Volume Befo...
- Hepatitis C Research-Jan 2012
- Fatigue in Cirrhosis Linked to Psychosocial Factor...
- Radical Liver Surgery, West Coast First
- Roche's Novel Tests for the Management of Hepatiti...
- Stanford discusses link between low vitamin D leve...
- Future treatment of patients with HCV cirrhosis
- What's new in HCV genotype 2 treatment
- Treatment of patients with genotype 3 chronic hepa...
- The future for the treatment of genotype 4 chronic...
- New targets for antiviral therapy of chronic hepat...
- Triple therapy for HCV geno1: telaprevir or bocepr...
- Hepatitis C Needs Higher Profile, Health Workers S...
- Chronic Liver Disease Hospitalizations Greater for...
- Why Have Cases of Liver Cancer Tripled?
- Hepatitis C vaccine: Oxford researchers' trial 'pr...
- ACH-1625 Protease Inhibitor Receives Fast Track Fo...
- Hepatitis C and Liver Health-Getting It Right In 2...
- Results:CF102 in the treatment of hepatocellular c...
- Mayo study links hepatitis C to liver cancer
- HCV News Ticker: American scientist arrested in st...
- Hepatitis C (DAA) drugs - The invaders and the bar...
-
►
March 2012
(15)
-
►
2011
(1577)
- ► December 2011 (75)
- ► November 2011 (81)
- ► October 2011 (70)
- ► September 2011 (83)
- ► August 2011 (142)
- ► April 2011 (161)
- ► March 2011 (176)
- ► February 2011 (140)
- ► January 2011 (199)
-
►
2010
(677)
- ► December 2010 (186)
- ► November 2010 (236)
- ► October 2010 (226)
- ► September 2010 (29)
GET TESTED
Click here to order a FREE Home Access Hepatitis C Test Kit
How Soon Should I Get Tested After Exposure ?
After the exposure (especially if the blood exposure involved another person known to have the hepatitis C virus), it is recommended that testing for the hepatitis C antibody be performed at 4 to 6 months after the exposure OR that testing for the hepatitis C virus itself (a test often called an HCV PCR or hepatitis C viral load test) be performed 4 to 6 weeks after the potential exposure. These tests are done to determine whether or not hepatitis C infection has occurred as a result of the exposure.;
FAIR USE NOTICE:
If this site contains copyrighted material the use of which has not been specifically authorized by the copyright owner, it is being made available in an effort to advance the understanding of the ethics dealing with medical practice, medical care, new drug research, drug trials, science and scientific research, human rights, social justice and, in addition, the law and politics which cover these areas. It is believed that this use constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed to visitors of this “HCV New Drugs Blog” without profit to the blog or to those who by visiting this blog have expressed interest in receiving the included information for research and educational purposes. The material in this site is provided for educational and informational purposes only, and is not intended to be a substitute for a health care provider's consultation. Please consult your own appropriate health care provider about the applicability of any opinions or recommendations with respect to your own symptoms or medical conditions. The information on this site does not constitute legal or technical advice
- New HCV Drugs
- Keeping current on the potential arrival of new, improved Hepatitis C drugs is a regular research venture for many who are living with the Hepatitis C virus. I was 43, a mother of three when I found out I had HCV. I went on to be treated successfully in 2000.(Intron A/Riba). Only people who have experienced a chronic illness understand the fear and apprehension felt with each step up the ladder, climbing closer to either medical treatment or a possible cure. These millions of people (I was one of them) who are living with chronic hepatitis C or just newly diagnosed are often left out in the cold, alone, with many unanswered questions. Enter the sleepless nights, anxiety, waking each day wondering what to do next. My blog is here to help you learn about HCV, the new drugs to treat this disease along with news and updates. Wishing you all a safe journey. Tina


0 comments: